Earnings Summary: Aurinia Pharmaceuticals Q4
Benzinga Insights 8 months ago
Earnings
The Q4 earnings report for Aurinia Pharmaceuticals (NASDAQ:AUPH) was released on Thursday, February 26, 2026 at 06:00 AM.
Here's what investors need to know about the latest announcement.
Earnings
Aurinia Pharmaceuticals beat estimated earnings by 628.57%, reporting an EPS of $1.53 versus an estimate of $0.21.
Revenue was up $17.25 million from the same period last year.
Overview of Past Earnings
The company beat on EPS by $0.07 in the last quarter, resulting in a 1.26% increase share price change the following day.
Here's a look at Aurinia Pharmaceuticals's past performance:
| Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|
| EPS Estimate | 0.16 | 0.16 | 0.10 | -0.02 |
| EPS Actual | 0.23 | 0.16 | 0.16 | 0.01 |
| Revenue Estimate | 68.01M | 64.26M | 61.06M | 59.94M |
| Revenue Actual | 73.47M | 70.01M | 62.47M | 59.87M |
To track all earnings releases for Aurinia Pharmaceuticals visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.